Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Advanced Search

Search

You could also try: favourite (50), preference (97)

InP RCODOX M(65) cyclophosphamide doxorubicin methotrexate rituximab vincristine

Description: Chemotherapy Protocol LYMPHOMA CYCLOPHOSPHAMIDE-DOXORUBICIN-METHOTREXATE-RITUXIMAB-VINCRISTINE (RCODOX-M) 6
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/InP-RCODOX-M65-cyclophosphamide-doxorubicin-methotrexate-rituximab-vincristine.pdf

MyelomaPAD-Bortezomib(SC)DexamethasoneDoxorubicinVer1

Description: Chemotherapy Protocol MULTIPLE MYELOMA PAD (SC)-BORTEZOMIB (SC)-DEXAMETHASONE-DOXORUBICIN Regimen Multiple Myeloma – PAD (SC)-Bortezomib (SC)-Dexame
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/MyelomaPAD-BortezomibSCDexamethasoneDoxorubicinVer1.pdf

MyelomaPAD-Bortezomib(IV)DexamethasoneDoxorubicinVer1

Description: Chemotherapy Protocol MULTIPLE MYELOMA PAD (IV)-BORTEZOMIB (IV)-DEXAMETHASONE-DOXORUBICIN Regimen Multiple Myeloma – PAD (IV)-Bortezomib (IV)-Dexame
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/MyelomaPAD-BortezomibIVDexamethasoneDoxorubicinVer1.pdf

MyelomaMPVBortezomib(SC)MelphalanPrednisolone(35day)Ver1

Description: Chemotherapy Protocol MULTIPLE MYELOMA MPV (SC)-BORTEZOMIB (SC)-MELPHALAN (PO)-PREDNISOLONE (35 day) Regimen Multiple Myeloma – MPV(SC)-Bortezomib
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/MyelomaMPVBortezomibSCMelphalanPrednisolone35dayVer1.pdf

MyelomaMPVBortezomib(IV)MelphalanPrednisolone(35day)Ver1

Description: Chemotherapy Protocol MULTIPLE MYELOMA MPV (IV)-BORTEZOMIB (IV)-MELPHALAN (PO)-PREDNISOLONE (35 day) Regimen Multiple Myeloma – MPV(IV)-Bortezomib
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/MyelomaMPVBortezomibIVMelphalanPrednisolone35dayVer1.pdf

Risk-reducing bilateral salpingo-oophorectomy (RRBSO) - patient information

Description: This factsheet explains what a risk-reducing bilateral salpingo-oophorectomy (RRBSO) is, what the procedure involves, and what the potential advantages
Url: /Media/UHS-website-2019/Patientinformation/Womenshealth/Risk-reducing-bilateral-salpingo-oophorectomy-RRBSO-3080-PIL.pdf

Data protection and confidentiality policy

Description: University Hospitals Southampton NHS Foundation Trust needs to collect and use information about people with whom it deals in order to
Url: /Media/UHS-website-2019/Docs/Policies/Data-protection-and-confidentiality-policy.pdf

Carboplatin(AUC5)-Paclitaxel (21 day)

Description: Chemotherapy Protocol GYNAECOLOGICAL CANCER CARBOPLATIN (AUC5)-PACLITAXEL (21 day) Regimen • Uterine-Carboplatin (AUC5)-Paclitaxel (21 day) Indication • Adjuvant trea
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Uterine-cancer/CarboplatinAUC5-Paclitaxel21day.pdf

TCC-ICA-PCAF-Round 1-Chairs-Report

Description: HEE/NIHR Pre-doctoral Clinical Academic Fellowship Scheme Round 1 (2018) Chairs’ Report ICA PCAF R1: Chairs’ Report Introduction The ICA Pro
Url: /Media/Southampton-Clinical-Research/Downloads/TCC-ICA-PCAF-Round-1-Chairs-Report.pdf

STHW841-V1-Biomerieux-Blood-culture-guidance

Description: BLOOD CULTURE A key investigation for diagnosis of bloodstream infections OUR SPECIAL THAN
Url: /Media/SUHTExtranet/DepartmentOfInfection/STHW841-V1-Biomerieux-Blood-culture-guidance.pdf

331 to 340 of 404

Previous … 32 33 34 35 36 … Next